Page 308 - Binder2

Edible biologics aren’t an alternative. They are a
platform—a foundation for redesigning how we treat
chronic disease, respond to pandemics, and make
immunotherapies more compatible with human biology.

They promise:

• Lower cost
• Higher accessibility
• Better immune tolerability
• And a new kind of infrastructure for therapeutic
production

This isn’t about replacing all biologics with plants. It’s
about asking: Where does this platform shine? Where is the
pain of existing systems the greatest? Where can a new
approach deliver the most value—not just clinically, but
structurally?

In a world shaped by climate instability, rising healthcare
costs, and growing demands for equity, the case for edible
biologics is no longer speculative. It’s structural.

The question isn’t whether they can work.

It’s whether we have the will to grow them.

5.6 - Medicine That Grows

306